CDT Equity (CDT) Other Non Operating Income (2022 - 2026)
CDT Equity's (CDT) quarterly Other Non Operating Income came in at -$408000.0 in Q1 2026, down 137.67% YoY from $1.1 million in Q1 2025, and down 1306.9% on a QoQ basis from -$29000.0 in Q4 2025.
CDT Equity (CDT) Other Non Operating Income (2022 - 2026) Analysis & Trends
CDT Equity (CDT) has 5 years of Other Non Operating Income data on file, last reported at -$408000.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 137.67% year-over-year to -$408000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$318000.0 (down 279.66% YoY) and the FY2025 annual result came in at $970000.0, up 208.99% from the prior year.
- Other Non Operating Income retreated to -$408000.0 in Q1 2026, from -$29000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $4.6 million in Q4 2023 to a low of -$1.4 million in Q4 2022.
- A 5-year average of $440733.3 and a median of $58000.0 in 2024 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2025 — Other Non Operating Income jumped 3767.86% — and 2026, when it sank 137.67%.
- Tracing CDT's Other Non Operating Income over 5 years: stood at -$1.4 million in 2022, then surged by 429.92% to $4.6 million in 2023, then tumbled by 122.93% to -$1.1 million in 2024, then surged by 97.26% to -$29000.0 in 2025, then slumped by 1306.9% to -$408000.0 in 2026.
- The last three Other Non Operating Income figures came in at -$408000.0 (Q1 2026), -$29000.0 (Q4 2025), and $104000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | CDT Equity | 1.55 Mn | 1.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.64 Mn |
| Mar 31, 2026 | -408,000.00 |
| Dec 31, 2025 | -29,000.00 |
| Sep 30, 2025 | 104,000.00 |
| Jun 30, 2025 | 15,000.00 |
| Mar 31, 2025 | 1.08 Mn |
| Dec 31, 2024 | -1.06 Mn |
| Sep 30, 2024 | 58,000.00 |
| Jun 30, 2024 | 93,000.00 |
| Mar 31, 2024 | 28,000.00 |
| Dec 31, 2023 | 4.61 Mn |
| Sep 30, 2023 | 3.30 Mn |
| Jun 30, 2023 | 270,000.00 |
| Mar 31, 2023 | -157,000.00 |
| Dec 31, 2022 | -1.40 Mn |
| Sep 30, 2022 | 95,000.00 |